Table 2.

Mean swelling ratios of (a) 10 K and (b) 35 K OPF composite formulations.

Formulation	PLL MW (kDa)	PLL Dosage (per hydrogel)	OPF MW (g/mol)	Mean swelling ratio
Day 1	Day 7	Day 14	Day 28
a.)
10 K Control	––	––	10 K	15.2±0.7b	17.3±0.6b	14.4±1.4	20.3±0.6a,b
10 K 50Hi	50	20 µg	10 K	17.4±0.7a	17.8±0.4a,b	13.4±2.4	17.8±1.5c
10 K 50Lo	50	500 ng	10 K	16.7±1.3a,b	17.6±0.8a,b	14.2±1.4	20.7±0.4a
10 K 225Hi	225	20 µg	10 K	18.5±0.7a	16.9±0.6b	14.5±0.2	19.2±0.8a,b,c
10 K 225Lo	225	500 ng	10 K	17.7±0.9a	19.4±1.7a	12.4±1.8	18.4±1.2b,c
b.)
35 K Control	––	––	35 K	16.3±0.6c	20.3±0.0a	20.3±0.2a	29.3±1.7a
35 K 50Hi	50	20 µg	35 K	18.9±1.3a,b	20.6±0.6a	20.7±1.0a	23.2±0.6b,c
35 K 50Lo	50	500 ng	35 K	17.7±1.7b,c	18.5±0.4b	20.1±0.6a,b	19.7±3.0c
35 K 225Hi	225	20 µg	35 K	20.9±0.2a	18.3±0.2b	18.4±0.6b	22.1±2.5c
35 K 225Lo	225	500 ng	35 K	21.0±0.9a	18.6±0.6b	20.4±1.2a	27.0±0.7a,b

For each time point, values not connected by the same letters (a, b, or c) are significantly different (p<0.05).